Loading
HS-10502 is an experimental pill being studied to block a DNA-repair enzyme in cancer cells.
The registry describes HS-10502 as a PARP1-specific selective inhibitor. The linked registry records distinguish recruiting, closed, and discontinued studies; those states do not establish comparative efficacy or approval.
The registry describes HS-10502 as a PARP1-specific selective inhibitor. Connects to PARP.
1.HS-10502 slips into a pocket on PARP.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"HS-10502" OR ABSTRACT:"HS-10502") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HS-10502, not a curated reading list.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Breast cancer (all types), Pancreatic ductal adenocarcinoma.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Ovarian cancer, Pancreatic ductal adenocarcinoma, Prostate cancer.
Shares PARP, Gastric & gastro-oesophageal junction cancer, Ovarian cancer, Breast cancer (all types).
Shares PARP, Breast cancer (all types), Triple-negative breast cancer (TNBC).
Shares PARP, Ovarian cancer, Prostate cancer.
Shares PARP, Ovarian cancer, Prostate cancer, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/